[68Ga]Ga-SSO120 PET/CT在儿童神经母细胞瘤中的生物分布与全身辐射剂量学
该研究纳入5例3-7岁IV期神经母细胞瘤患儿,给予2 MBq/kg [68Ga]Ga-SSO120后行60分钟动态及静态PET/CT扫描,共评估17个病灶;结果显示该显像安全、有效剂量低,60分钟时肿瘤SULmax中位4.28、肿瘤/肝脏比值中位4.05,30与60分钟图像采集似乎等效。
要点
- 儿童神经母细胞瘤患者中[68Ga]Ga-SSO120 PET/CT安全,有效剂量0.088±0.014 mSv/MBq。
- 60分钟时肿瘤SULmax中位4.28、肿瘤/肝脏比值中位4.05,靶本比良好。
- 膀胱受照最高(22.3±4.3 μSv/MBq),30与60分钟采集似乎等效。
核心结论
- [68Ga]Ga-SSO120 PET/CT在儿童神经母细胞瘤患者中安全,有效辐射剂量低,能以良好靶本比检出病灶。
研究设计与样本
- 前瞻性研究纳入5例3-7岁IV期神经母细胞瘤患者,给予2 MBq/kg [68Ga]Ga-SSO120后行60分钟动态扫描和静态PET/CT扫描。
主要发现
- 共评估17个神经母细胞瘤病灶;中位给药活度2.5 MBq/kg(范围2.1-2.8 MBq/kg)。
- 注射后60分钟,肿瘤SULmax中位4.28(范围1.89-18.07),SULpeak中位2.71(范围1.23-14.77)。
- 肿瘤/肝脏比值中位4.05;膀胱受照最高,为22.3±4.3 μSv/MBq。
- 全身有效剂量为0.088±0.014 mSv/MBq;30与60分钟图像采集似乎等效。
临床怎么用
- 可考虑用[68Ga]Ga-SSO120 PET/CT作为儿童神经母细胞瘤SSTR显像的替代方案,注射后30或60分钟采集似乎均可。
局限性
- 样本量仅5例、共17个病灶,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical standard for neuroblastoma detection is based on targeting the norepinephrine transporter with [123I]MIBG, which has several challenges. Imaging the somatostatin receptor (SSTR) is a strong alternative. In contrast to standard DOTATATE, SSTR antagonist imaging with [68Ga]Ga-satoreotide trizoxetan ([68Ga]-SSO120) can potentially improve lesion detection as it targets both active and inactive SSTRs. We present the biodistribution and radiation exposure results of [68Ga]Ga-SSO120 PET/CT imaging in pediatric patients with neuroblastoma. Methods: Patients age 3-7 y with stage 4 neuroblastoma received 2 MBq/kg of [68Ga]Ga-SSO120, followed by a 60-min dynamic scan and a static PET/CT scan. SUV normalized to lean body mass (SULmax, SULmean, SULpeak) and time-activity curves were measured for suspected lesions and various tissue compartments. Tumor-to-liver and tumor-to-blood pool ratios were calculated. Radiation doses to various organs and the total-body effective dose were computed. Results: Five patients underwent dynamic [68Ga]Ga-SSO120 PET/CT scanning, with a total of 17 neuroblastoma lesions. The median administered activity was 2.5 MBq/kg (range, 2.1-2.8 MBq/kg). At 60 min postinjection, the median tumor SULmax and SULpeak were 4.28 (range, 1.89-18.07) and 2.71 (range, 1.23-14.77), respectively, and the median tumor-to-liver ratio was 4.05. The highest exposure was in the bladder (22.3 ± 4.3 μSv/MBq). The effective dose was 0.088 ± 0.014 mSv/MBq. Conclusion: [68Ga]Ga-SSO120 PET/CT was safe in pediatric patients with neuroblastoma, with a low effective radiation dose, and detected neuroblastoma lesions with a good target-to-noise ratio. Image acquisition at 30 and 60 min postinjection seemed equivalent.
引用
- Teles L, van Rooij R, van Noesel MM, et al. [68Ga]Ga-SSO120 PET/CT Imaging in Pediatric Patients with Neuroblastoma: Biodistribution and Whole-Body Radiation Dosimetry. J Nucl Med. 2026. PMID: 42850043. doi:10.2967/jnumed.126.272321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。